Qingsong Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qingsong Sun has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Hong Sun
Department of Pharmacy, Eye & ENT Hospital, Fudan University, Shanghai, China
1 shared publication - Hongmei Zhao
Department of Emergency The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University Huai'an China
1 shared publication - Jia‐Li Tao
Department of Emergency The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University Huai'an China
1 shared publication Lili Gao
Department of Emergency, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University
1 shared publication- Man Luo
Department of Emergency, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huaian, China
1 shared publication Weiqin Wu
Department of Emergency, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University
1 shared publication
Latest Publications
- Open Access
- 6 April 2026
- Published by Taylor & Francis in Renal Failure
- Vol. 48 (1) , 2641853
A multimodal predictive model incorporating transcriptomic-guided blood biomarkers and clinical variables for sepsis-associated acute kidney injury
Sepsis-associated acute kidney injury (SA-AKI) is a major complication in the intensive care unit (ICU), and early risk stratification remains challenging. This study developed a multimodal predictive model integrating clinical variables with transcriptomic-guided blood biomarkers. Differentially expressed genes were identified from the Gene Expression Omnibus (GEO) database, and cluster of differentiation 177 (CD177) and interleukin-18 receptor 1 (IL18R1) were identified as immune-activation biomarkers associated with SA-AKI. In a retrospective cohort of 188 septic patients (89 SA-AKI), gene expression was quantified by quantitative polymerase chain reaction (qPCR) using blood samples collected within 24 h of ICU admission. Clinical predictors including the Sequential Organ Failure Assessment (SOFA) score, mean arterial pressure (MAP), blood urea nitrogen (BUN), C-reactive protein (CRP), and mechanical ventilation were incorporated using least absolute shrinkage and selection operator (LASSO) feature selection and logistic regression. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curves, and decision-curve analysis in an internal test cohort and an external cohort (n = 83). SOFA score, MAP, BUN, CRP, and CD177 were independent predictors of SA-AKI. The combined model showed excellent discrimination (AUC 0.989) with good calibration (Hosmer-Lemeshow p = 0.996; Brier score 0.040) and remained robust in external validation (AUC 0.909). Integrating immune biomarkers with routine clinical parameters may improve early prediction of SA-AKI, although multicenter prospective validation is required.
- 6 April 2026
- Published by Taylor & Francis in Renal Failure
- Vol. 48 (1) , 2641853
Open AccessA multimodal predictive model incorporating transcriptomic-guided blood biomarkers and clinical variables for sepsis-associated acute kidney injury
Sepsis-associated acute kidney injury (SA-AKI) is a major complication in the intensive care unit (ICU), and early risk stratification remains challenging. This study developed a multimodal predictive model integrating clinical variables with transcriptomic-guided blood biomarkers. Differentially expressed genes were identified from the Gene Expression Omnibus (GEO) database, and cluster of differentiation 177 (CD177) and interleukin-18 receptor 1 (IL18R1) were identified as immune-activation biomarkers associated with SA-AKI. In a retrospective cohort of 188 septic patients (89 SA-AKI), gene expression was quantified by quantitative polymerase chain reaction (qPCR) using blood samples collected within 24 h of ICU admission. Clinical predictors including the Sequential Organ Failure Assessment (SOFA) score, mean arterial pressure (MAP), blood urea nitrogen (BUN), C-reactive protein (CRP), and mechanical ventilation were incorporated using least absolute shrinkage and selection operator (LASSO) feature selection and logistic regression. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curves, and decision-curve analysis in an internal test cohort and an external cohort (n = 83). SOFA score, MAP, BUN, CRP, and CD177 were independent predictors of SA-AKI. The combined model showed excellent discrimination (AUC 0.989) with good calibration (Hosmer-Lemeshow p = 0.996; Brier score 0.040) and remained robust in external validation (AUC 0.909). Integrating immune biomarkers with routine clinical parameters may improve early prediction of SA-AKI, although multicenter prospective validation is required.
- Open Access
- 12 February 2020
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 36 (6) , 417-422
Overexpression of tripartite motif containing 26 inhibits non‐small cell lung cancer cell growth by suppressing PI3K/AKT signaling
It has been reported that tripartite motif containing 26 (TRIM26) is involved in the tumorigenesis of some cancers, but its function in non‐small cell lung cancer (NSCLC) is still unclear. In this study, we found that TRIM26 was markedly down‐regulated in both of NSCLC tumor tissues and cell lines. Additionally, high expression of TRIM26 in NSCLC patients predicted a positive index for patients' overall survival. What is more, overexpression of TRIM26 significantly suppressed NSCLC cell growth. Our further studies indicated that overexpression of TRIM26 inhibited the phosphorylation of PI3K p85 and AKT. And overexpressed TRIM26 regulated cell cycle‐related genes' expression, including downregulating CDK4, Cyclin A, Cyclin D1, Cyclin D3, and Cyclin E, and upregulating p27 expression. Finally, we found that TRIM26 up‐regulated PTEN expression by stabilizing PTEN protein in NSCLC cells. Collectively, our present study indicated that TRIM26 was decreased in NSCLC and overexpression of TRIM26 inhibited NSCLC cell growth by suppressing PI3K/AKT pathway, which suggested that TRIM26 could be as a potential target for the treatment of NSCLC in the future.
- 12 February 2020
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 36 (6) , 417-422
Open AccessOverexpression of tripartite motif containing 26 inhibits non‐small cell lung cancer cell growth by suppressing PI3K/AKT signaling
It has been reported that tripartite motif containing 26 (TRIM26) is involved in the tumorigenesis of some cancers, but its function in non‐small cell lung cancer (NSCLC) is still unclear. In this study, we found that TRIM26 was markedly down‐regulated in both of NSCLC tumor tissues and cell lines. Additionally, high expression of TRIM26 in NSCLC patients predicted a positive index for patients' overall survival. What is more, overexpression of TRIM26 significantly suppressed NSCLC cell growth. Our further studies indicated that overexpression of TRIM26 inhibited the phosphorylation of PI3K p85 and AKT. And overexpressed TRIM26 regulated cell cycle‐related genes' expression, including downregulating CDK4, Cyclin A, Cyclin D1, Cyclin D3, and Cyclin E, and upregulating p27 expression. Finally, we found that TRIM26 up‐regulated PTEN expression by stabilizing PTEN protein in NSCLC cells. Collectively, our present study indicated that TRIM26 was decreased in NSCLC and overexpression of TRIM26 inhibited NSCLC cell growth by suppressing PI3K/AKT pathway, which suggested that TRIM26 could be as a potential target for the treatment of NSCLC in the future.